Vancouver, British Columbia, Canada– Andira Pharmaceuticals welcomes to its board of directors, Dr. Ethan Russo, a global pioneer in the development of cannabinoid therapeutics. Andira is a privately-held biopharmaceutical firm dedicated to the advancement of cannabinoid-based therapeutics for infectious disease and oncology indications in the traditional pharmaceutical business model.
Andira Founder and CEO, Dana Lambert, PhD says, “The addition of Dr. Ethan Russo to Andira’s Board of Directors directly aligns with our vision of bringing better medicines into the world while facilitating the greatest possible value to patients and shareholders alike. His acceptance of this role is both an honor and a privilege to our organization.”
Dr. Russo brings to Andira over two decades of experience in the cannabinoid pharmaceutical development space. Formerly Senior Medical Advisor to GW Pharmaceuticals, Dr. Russo served as the Medical Monitor and Study Physician for the clinical trials for the first-to-market cannabinoid prescription drugs Sativex® and Epidiolex®. Dr. Russo has played major roles in more than 23 clinical trials in the areas of epilepsy, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), autism, neuropathic pain and cancer pain, and he has published over 50 peer-reviewed journal articles and seven books.
“I am deeply honored to be associated with Andira Pharmaceuticals,” says Dr. Russo. “Dana Lambert is a brilliant researcher and pharmaceutical development expert who has assembled a world-class team to realize her aspirational goals of bringing innovative cannabis-based medicines and delivery systems to market to treat metastatic cancer and antibiotic-resistant bacterial infections. This work portends to be a revelation and game-changer in medicine. In my 24 years working in the cannabinoid research and development arena, Andira hosts the most exciting therapeutic programs I have encountered.”
Dr. Lambert concludes, “Given Dr. Russo’s world-class expertise and astounding track record in cannabinoid-based pharmaceutical development, Andira is geared up to make a powerful impact through each of its therapeutic programs.”
For all media inquiries please contact info@andira.ca
